Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Social Sciences
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2772-316X
  • E-ISSN: 2772-3178

Abstract

In August 2023, the Italian Health Ministry listed cannabidiol (CBD) as a drug of abuse. This rekindled the debate on the medical and non-medical use of cannabis. The most discussed topics are risks related to the use of cannabis, the decriminalization/legalization of recreational cannabis, and use of cannabis-based drugs for medical purposes. The decision to include CBD in the “Unique Text for drugs of abuse” (DPR.309/1990), along with the already included main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), is not particularly relevant to such ongoing discussions. Even when it comes to cannabis-based drugs for medical purposes, such a decision will have a minimum impact on CBD-based medical prescriptions. Instead, a high economic impact is expected on CBD-based products sold online or in specific shops, including the so-called “cannabis-light”, formally sold as a “technological product” for collection purposes but used as over-the-counter drugs for the treatment of several medical conditions. Cannabis-light products have reduced regular drug consumption by about 10%. Also, they are not entirely safe, as the actual content of THC may significantly differ from the one stated, carrying unexpected health risks. Further, CBD is likely not a drug with addictive potential; however, its uncontrolled use for medical purposes needs to be regulated as the court battles are ongoing.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/css/10.2174/012772316X295557240417104307
2024-04-26
2024-11-23

  • From This Site

    /content/journals/css/10.2174/012772316X295557240417104307
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Italian Health Ministry. Law decree.Available from: https://www.gazzettaufficiale.it/eli/id/2023/08/21/23A04729/SG
    [Google Scholar]
  2. Italian Health Ministry Italian Health Ministry. Law decreeAvailable from: https://www.gazzettaufficiale.it/eli/id/2020/10/15/20A05476/sg
    [Google Scholar]
  3. ColizziM. BhattacharyyaS. Neurocognitive effects of cannabis: Lessons learned from human experimental studies. Prog. Brain Res.201824217921610.1016/bs.pbr.2018.08.010 30471680
     [Google Scholar]
  4. WrightS. MettsJ. Recreational cannabinoid use: The hazards behind the “high”.J. Fam. Pract.20166511770779 28087865
     [Google Scholar]
  5. ColizziM. RuggeriM. BhattacharyyaS. Unraveling the intoxicating and therapeutic effects of cannabis ingredients on psychosis and cognition.Front. Psychol.20201183310.3389/fpsyg.2020.00833 32528345
     [Google Scholar]
  6. ConnorJ.P. StjepanovićD. Le FollB. HochE. BudneyA.J. HallW.D. Cannabis use and cannabis use disorder.Nat. Rev. Dis. Primers2021711610.1038/s41572‑021‑00247‑4 33627670
     [Google Scholar]
  7. AssanangkornchaiS. KalayasiriR. Ratta-aphaW. TanareeA. Effects of cannabis legalization on the use of cannabis and other substances.Curr. Opin. Psychiatry202336428328910.1097/YCO.0000000000000868 37185310
     [Google Scholar]
  8. McGintyE.E. NiederdeppeJ. HeleyK. BarryC.L. Public perceptions of arguments supporting and opposing recreational marijuana legalization.Prev. Med.201799808610.1016/j.ypmed.2017.01.024 28189806
     [Google Scholar]
  9. (aWorld Health Organization (WHO) Drugs. Drugs (psychoactive): Cannabidiol (compound of cannabis).https://www.who.int/news-room/questions-and-answers/item/cannabidiol-(compound-of-cannabis)#:~:text=It%20has%20been%20widely%20reported,compounds%20of%20the%20cannabis%20plant
  10. (b CarrieriV. MadioL. PrincipeF. Do-it-yourself medicine? the impact of light cannabis liberalization on prescription drugs.J. Health Econ.20207410237110.1016/j.jhealeco.2020.102371 32920244
     [Google Scholar]
  11. PavlovicR. NennaG. CalviL. PanseriS. BorgonovoG. GiupponiL. CannazzaG. GiorgiA. Quality traits of “cannabidiol oils”: Cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations.Molecules2018235123010.3390/molecules23051230 29783790
     [Google Scholar]
  12. Italian Health Ministry. Recommendations for the doctor prescribing the herbal substance cannabis FM2 inflorescences.Available from: https://www.salute.gov.it/imgs/C_17_pagineAree_4589_listaFile_itemName_2_file.pdf
    [Google Scholar]
/content/journals/css/10.2174/012772316X295557240417104307
Loading

  • Article Type:     Editorial
Keyword(s): Cannabinoids; cannabis-light; medications; pharmaceutical legislation; pharmacological treatment; psychoactive component
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test